<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03665467</url>
  </required_header>
  <id_info>
    <org_study_id>GPIU</org_study_id>
    <nct_id>NCT03665467</nct_id>
  </id_info>
  <brief_title>The Global Prevalence of Infections in Urology Study</brief_title>
  <acronym>GPIU</acronym>
  <official_title>The Global Prevalence of Infections in Urology Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Association of Urology Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Association of Urology Research Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Urology departments from all over the world are invited to join the Global Prevalence Study
      on Infections in Urology (GPIU-study) and the GPIU Prostate Biopsy Side Study. The GPIU study
      is taking part annually in November since 2003. European urologists were the first group of
      specialist to register hospital acquired infections on an international level. More than
      20.000 patients have been screened and more than 2000 patients are currently listed in this
      database.

      Why? Infectious complications after urological procedures, such as prostate biopsy and
      increasing antimicrobial resistance are posing significant threats to modern urology The
      GPIU-study is a combined quality improvement initiative and a scientific study. Once the
      participating departments have filled in the report forms they will get access to statistics
      showing the accumulated results for all participating hospitals. The participants can
      anonymously compare their own results with hospitals from all over the World. The GPIU-study
      application has been designed as an instrument to ongoing follow-up of the development of
      important factors related to infection on international, national and local levels.

      Take responsibility for the future of urology - join the GPIU-studies! http://gpiu.esiu.org

      Prof. Dr. Florian M.E. Wagenlehner, MD, PhD Clinic for Urology, Pediatric Urology and
      Andrology University Clinic Giessen, Germany GPIU study coordinator

      Prof. Truls E. Bjerklund Johansen, MD, PhD Urology Department, Oslo University Hospital,
      Chairman ESIU Oslo (NO) GPIU Study coordinator

      Zafer Tandogdu Northern Institute for Cancer Research Newcastle University, UK

      Dominic Althaus Software engineer Giessen (Ger)
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 30, 2003</start_date>
  <completion_date type="Anticipated">November 30, 2018</completion_date>
  <primary_completion_date type="Actual">November 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Health care associated infection episode</measure>
    <time_frame>an infection onset 48 hours after admission to hospital or after an intervention</time_frame>
    <description>Health Care Associated Infections per definition of the Center for Disease Control</description>
  </primary_outcome>
  <enrollment type="Actual">2000</enrollment>
  <condition>Hospital Infection</condition>
  <condition>Urinary Tract Infections</condition>
  <eligibility>
    <study_pop>
      <textblock>
        -hospitalised urological patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  On the chosen single study day at 08:00 AM local time all patients present on the ward
             of the participating institution are included

          -  The presence of urinary tract infections (UTI) according to the CDC definitions during
             their entire hospital stay are documented and audited and the patients are categorized
             as having or not having a UTI and/or

          -  The presence of surgical site infection (SSI) according to the CDC definitions during
             their entire hospital stay are documented and audited and the patients are categorized
             as having or not having a SSI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florian Wagenlehner, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Giessen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zafer Tandogdu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Truls Erik Bjerklund Johansen, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Oslo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bela Koves, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jahn Ferenc South Pest Teaching Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Giessen University, Medical School</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jahn Ferenc South Pest Teaching Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1204</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo University</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH9 1HN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Norway</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Wagenlehner F, Tandogdu Z, Bartoletti R, Cai T, Cek M, Kulchavenya E, Köves B, Naber K, Perepanova T, Tenke P, Wullt B, Bogenhard F, Johansen TE. The Global Prevalence of Infections in Urology Study: A Long-Term, Worldwide Surveillance Study on Urological Infections. Pathogens. 2016 Jan 19;5(1). pii: E10. doi: 10.3390/pathogens5010010.</citation>
    <PMID>26797640</PMID>
  </reference>
  <reference>
    <citation>Wagenlehner F, Tandogdu Z, Bartoletti R, Cai T, Cek M, Kulchavenya E, Köves B, Naber K, Perepanova T, Tenke P, Wullt B, Bogenhard F, Bjerklund Johansen TE; GPIU Investigators. The Global Prevalence of Infections in Urology (GPUI) Study: A Worldwide Surveillance Study in Urology Patients. Eur Urol Focus. 2016 Oct;2(4):345-347. doi: 10.1016/j.euf.2016.03.004. Epub 2016 Apr 1.</citation>
    <PMID>28723463</PMID>
  </reference>
  <reference>
    <citation>Tandoğdu Z, Bartoletti R, Cai T, Çek M, Grabe M, Kulchavenya E, Köves B, Menon V, Naber K, Perepanova T, Tenke P, Wullt B, Johansen TE, Wagenlehner F. Antimicrobial resistance in urosepsis: outcomes from the multinational, multicenter global prevalence of infections in urology (GPIU) study 2003-2013. World J Urol. 2016 Aug;34(8):1193-200. doi: 10.1007/s00345-015-1722-1. Epub 2015 Dec 11.</citation>
    <PMID>26658886</PMID>
  </reference>
  <reference>
    <citation>Cek M, Tandoğdu Z, Wagenlehner F, Tenke P, Naber K, Bjerklund-Johansen TE. Healthcare-associated urinary tract infections in hospitalized urological patients--a global perspective: results from the GPIU studies 2003-2010. World J Urol. 2014 Dec;32(6):1587-94. doi: 10.1007/s00345-013-1218-9. Epub 2014 Jan 23.</citation>
    <PMID>24452449</PMID>
  </reference>
  <reference>
    <citation>Tandogdu Z, Cek M, Wagenlehner F, Naber K, Tenke P, van Ostrum E, Johansen TB. Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study. World J Urol. 2014 Jun;32(3):791-801. doi: 10.1007/s00345-013-1154-8. Epub 2013 Aug 24.</citation>
    <PMID>23979151</PMID>
  </reference>
  <reference>
    <citation>Çek M, Tandoğdu Z, Naber K, Tenke P, Wagenlehner F, van Oostrum E, Kristensen B, Bjerklund Johansen TE; Global Prevalence Study of Infections in Urology Investigators. Antibiotic prophylaxis in urology departments, 2005-2010. Eur Urol. 2013 Feb;63(2):386-94. doi: 10.1016/j.eururo.2012.09.038. Epub 2012 Sep 25.</citation>
    <PMID>23031676</PMID>
  </reference>
  <reference>
    <citation>Wagenlehner FM, van Oostrum E, Tenke P, Tandogdu Z, Çek M, Grabe M, Wullt B, Pickard R, Naber KG, Pilatz A, Weidner W, Bjerklund-Johansen TE; GPIU investigators. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. Eur Urol. 2013 Mar;63(3):521-7. doi: 10.1016/j.eururo.2012.06.003. Epub 2012 Jun 12.</citation>
    <PMID>22704727</PMID>
  </reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>July 8, 2018</study_first_submitted>
  <study_first_submitted_qc>September 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2018</study_first_posted>
  <last_update_submitted>September 8, 2018</last_update_submitted>
  <last_update_submitted_qc>September 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Giessen</investigator_affiliation>
    <investigator_full_name>Florian M E Wagenlehner</investigator_full_name>
    <investigator_title>Professor of Urology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Cross Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Investigators will be able to download their own submitted data
Investigators will be able to access an online summary statistics of the annual pooled sample
Investigators will be able to compare their own summary statistics with other centers on the study website.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Annual</ipd_time_frame>
    <ipd_access_criteria>Study investigators will be able to access their own data and in addition the summary statistics of the pooled sample on an annual basis.</ipd_access_criteria>
    <ipd_url>http://gpiu.esiu.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

